461 related articles for article (PubMed ID: 29123012)
1. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.
Eiber M; Herrmann K; Calais J; Hadaschik B; Giesel FL; Hartenbach M; Hope T; Reiter R; Maurer T; Weber WA; Fendler WP
J Nucl Med; 2018 Mar; 59(3):469-478. PubMed ID: 29123012
[TBL] [Abstract][Full Text] [Related]
2. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Seifert R; Emmett L; Rowe SP; Herrmann K; Hadaschik B; Calais J; Giesel FL; Reiter R; Maurer T; Heck M; Gafita A; Morris MJ; Fanti S; Weber WA; Hope TA; Hofman MS; Fendler WP; Eiber M
Eur Urol; 2023 May; 83(5):405-412. PubMed ID: 36935345
[TBL] [Abstract][Full Text] [Related]
3. Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria.
Demirci E; Akyel R; Caner B; Alan-Selçuk N; Güven-Meşe Ş; Ocak M; Kabasakal L
Nucl Med Commun; 2020 Aug; 41(8):759-767. PubMed ID: 32453205
[TBL] [Abstract][Full Text] [Related]
4. PSMA Ligands for PET Imaging of Prostate Cancer.
Schwarzenboeck SM; Rauscher I; Bluemel C; Fendler WP; Rowe SP; Pomper MG; Afshar-Oromieh A; Herrmann K; Eiber M
J Nucl Med; 2017 Oct; 58(10):1545-1552. PubMed ID: 28687599
[TBL] [Abstract][Full Text] [Related]
5. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT.
Klein Nulent TJW; Valstar MH; de Keizer B; Willems SM; Smit LA; Al-Mamgani A; Smeele LE; van Es RJJ; de Bree R; Vogel WV
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):478-486. PubMed ID: 29523427
[TBL] [Abstract][Full Text] [Related]
6. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
7. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification and staging in prostate cancer with prostatic specific membrane antigen PET/CTObjective: A one-stop-shop.
Gupta M; Choudhury PS; Rawal S; Goel HC; Singh A; Talwar V; Sahoo SK
Hell J Nucl Med; 2017; 20 Suppl():156. PubMed ID: 29324926
[TBL] [Abstract][Full Text] [Related]
9. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
10. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous whole-body
Freitag MT; Kesch C; Cardinale J; Flechsig P; Floca R; Eiber M; Bonekamp D; Radtke JP; Kratochwil C; Kopka K; Hohenfellner M; Stenzinger A; Schlemmer HP; Haberkorn U; Giesel F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):340-347. PubMed ID: 29038888
[TBL] [Abstract][Full Text] [Related]
12.
Fendler WP; Eiber M; Beheshti M; Bomanji J; Ceci F; Cho S; Giesel F; Haberkorn U; Hope TA; Kopka K; Krause BJ; Mottaghy FM; Schöder H; Sunderland J; Wan S; Wester HJ; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1014-1024. PubMed ID: 28283702
[TBL] [Abstract][Full Text] [Related]
13. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
15. Whole-body uptake classification and prostate cancer staging in
Capobianco N; Sibille L; Chantadisai M; Gafita A; Langbein T; Platsch G; Solari EL; Shah V; Spottiswoode B; Eiber M; Weber WA; Navab N; Nekolla SG
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):517-526. PubMed ID: 34232350
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
17. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer.
Bagguley D; Ong S; Buteau JP; Koschel S; Dhiantravan N; Hofman MS; Emmett L; Murphy DG; Lawrentschuk N
Future Oncol; 2021 Jun; 17(17):2225-2241. PubMed ID: 33724868
[TBL] [Abstract][Full Text] [Related]
18. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
20. Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Hofman MS; Iravani A; Nzenza T; Murphy DG
Urol Clin North Am; 2018 Aug; 45(3):503-524. PubMed ID: 30031469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
